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Abstract
Background: While doxorubicin (DOX) is widely used in cancer chemotherapy, long-term severe
cardiotoxicity limits its use. This is the first report of the chemoprotective efficacy of a relatively
new thiol antioxidant, N-acetylcysteine amide (NACA), on DOX-induced cell death in
cardiomyocytes. We hypothesized that NACA would protect H9c2 cardiomyocytes from DOX-
induced toxicity by reducing oxidative stress. Accordingly, we determined the ability of NACA to
mitigate the cytotoxicity of DOX in H9c2 cells and correlated these effects with the production of
indicators of oxidative stress.
Results: DOX at 5 μM induced cardiotoxicity while 1) increasing the generation of reactive
oxygen species (ROS), 2) decreasing levels and activities of antioxidants and antioxidant enzymes
(catalase, glutathione peroxidase, glutathione reductase) and 3) increasing lipid peroxidation.
NACA at 750 μM substantially reduced the levels of ROS and lipid peroxidation, as well as
increased both GSH level and GSH/GSSG ratio. However, treating H9c2 cells with NACA did little
to protect H9c2 cells from DOX-induced cell death.
Conclusion: Although NACA effectively reduced oxidative stress in DOX-treated H9c2 cells, it
had minimal effects on DOX-induced cell death. NACA prevented oxidative stress by elevation of
GSH and CYS, reduction of ROS and lipid peroxidation, and restoration of antioxidant enzyme
activities. Further studies to identify oxidative stress-independent pathways that lead to DOX-
induced cell death in H9c2 are warranted.
Background
Doxorubicin (Adriamycin®) is a potent and broad-spec-
trum antineoplastic agent used in the treatment of a vari-
ety of cancers, including leukemias, lymphomas, and
breast, lung, and ovarian cancers [1]. The antitumor
mechanism of DOX involves inhibition of both topoi-
somerase II and DNA synthesis [2]. Unfortunately, long-
term treatment with DOX is limited by irreversible cardi-
omyopathic changes and consequent congestive heart
failure. The cardiotoxicity is believed to be caused by the
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generation of free radicals leading to dysfunction of mito-
chondria in cardiac cells, interference with cell calcium
regulation, and bioenergetic failure [3-5].
The  in vitro metabolism of DOX by cardiac and liver
microsomal membranes includes enzymes such as
cytosolic xanthine oxidase, microsomal nicotinamide
adenine dinucleotide phosphate (NADPH)-cytochrome
P450 reductase, which is present in all tissues (e.g., heart,
liver), and mitochondrial cytosolic NADPH dehydroge-
nase, which is uniquely present in cardiac cells [6,7]. DOX
is bio-reduced to a semiquinone free radical that rapidly
undergoes 1) further reduction to a hydroquinone, 2) for-
mation of covalent adducts with DNA or proteins, or 3)
transfer of the unpaired electron to an electron acceptor
[8]. In the presence of oxygen, the semiquinone radical
produces O2
.-, which can be converted by superoxide dis-
mutase to hydrogen peroxide (H2O2). In the presence of
reduced iron, H2O2 is decomposed to the highly toxic
hydroxyl radical (HO.). Superoxide, H2O2, and HO. cause
peroxidation of unsaturated membrane lipids and induce
irreversible tissue damage by inactivating key proteins and
enzymes present in the cardiac sarcoplasmic reticulum
and in the mitochondrial respiratory chain [9-11].
Considerable attention has been paid to alleviate DOX-
induced oxidative stress with DOX by compounds that 1)
function as antioxidants or 2) regulate the expression of
endogenous antioxidants. For example, carvedilol [12],
melatonin and its synthetic derivatives [4,13], metal-
lothionein [14], iron and iron chelators [15] have been
tested. To date, dexrazoxane is the only iron chelator that
has been approved for reducing DOX-induced cardiotox-
icity. However, this chelator also reduces DOX's antineo-
plastic activity, causes myelosuppression, and may
increase the risk of developing secondary malignancies
[16,17].
The thiol group plays an important role in biological sys-
tem. Thiol oxidation can result in protein structure altera-
tion leading to compromise of protein function. The thiol
group appearing in a variety of proteins or nonproteins,
e.g. glutathione (GSH), undergoes reversible thiol-
disulfide interactions to mediate the oxidant-induced
stress [18]. The use of biothiols, such as GSH, N-acetyl-
cysteine (NAC), homocysteine, cysteine (CYS), and γ-
glutamyl cysteine, to mitigate acute oxidative stress
induced by anticancer drugs has long been proposed,
though their efficacies have not been fully evaluated. NAC
did not provide significant antioxidant effects, presuma-
bly due to its low lipid solubility that limits its bioavaila-
bility [19]. For instance, NAC at 140 mg/kg body weight
failed to prevent acute DOX-induced cardiotoxicity [20].
The carboxyl group in NAC is negatively charged at phys-
iological pH, limiting its ability to cross cell membranes.
Recently, N-acetylcysteine amide (NACA), a structural
analogue of NAC, was synthesized and evaluated in cer-
tain in vivo and in vitro models. Replacing the carboxyl
group with an amide increases lipophilicity, allowing it to
cross cell membranes. Two studies have shown that NACA
could cross the blood-brain barrier, chelate Cu2+ (which
catalyzes free radical formation), scavenge free-radicals,
protect red blood cells from oxidative stress, and prevent
ROS-induced activation of c-Jun N-terminal protein
kinase (JNK), mitogen-activated protein kinase MAPK
(p38), and matrix metalloproteinases [21,22].
The ability of NACA to protect cardiomyocytes from
DOX-induced toxicity has not been investigated. We
hypothesized that NACA would protect H9c2 cardiomyo-
cytes by reducing oxidative stress. Accordingly, we deter-
mined the ability of NACA to mitigate the cytotoxicity of
DOX in H9c2 cells and correlated these effects with the
attenuation of oxidative stress.
Results
Cytotoxicity of doxorubicin (DOX) and N-acetylcysteine 
amide (NACA) on H9c2 cells
To determine a sublethal concentration of NACA for the
study on its ability to protect H9c2 cells from DOX-
induced toxicity, we first exposed cells with NACA at 0.25
mM, 0.50 mM, 0.75 mM, 1 mM, 2 mM, 5 mM, 10 mM,
and 20 mM for 24 h. A comparative study was conducted
on NAC. Both NACA and NAC induced significant cyto-
toxicity at concentrations ≥ 10 mM and 2.0 mM, respec-
tively. Cell viability was further reduced by 80% at 20 mM
of NACA or NAC (p < 0.01, n = 5) (Fig. 1). At 1.0 mM of
NACA or NAC, the cell viability is comparable to the con-
H9c2 cell viability after 24 h exposure to NACA and NAC at  250 μM, 500 μM, 750 μM, 1 mM, 2 mM, 5 mM, 10 mM, and  20 mM Figure 1
H9c2 cell viability after 24 h exposure to NACA and 
NAC at 250 μM, 500 μM, 750 μM, 1 mM, 2 mM, 5 mM, 
10 mM, and 20 mM. Values are mean ± SD from three 
independent experiments. Significance indicated by: *p < 0.05 
NACA vs. control group; αp < 0.05 NAC vs. control group.
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trol group. Thus, we conservatively selected both antioxi-
dants at 0.75 mM in our subsequent studies for
comparison purpose.
Effect of NACA on DOX-induced cytotoxicity
The DOX-induced toxicity was both concentration- and
time-dependent in the range of 0.25 – 100 μM. Cell via-
bility at 0.75 μM was reduced by ca. 25%, 60%, and 70%
at 24 h, 48 h, and 72 h, respectively (Fig. 2). To study the
protective effect of NACA and NAC on DOX-induced tox-
icity, cells were treated with 750 μM NACA or NAC for 2
h prior to incubation with freshly prepared cell medium
containing both DOX and NACA or NAC at designated
final concentrations. Both NACA and NAC had minimal
protective effects on cytotoxicity at all concentrations of
DOX and over a period of 72 h exposure. NACA was most
effective at 5 μM of DOX. Accordingly, 5 μM DOX was
used in the subsequent studies on oxidative stress.
DOX-induced oxidative stress in the presence or absence 
of NACA
Treatment with 5 μM DOX increased ROS by 56% com-
pared to the control group (p < 0.05, n = 3). The increase
was reduced to the control group level in the presence of
750 μM NACA (p > 0.05, n = 4) (Fig. 3). The endogenous
levels of GSH and CYS were significantly reduced after a
24 h exposure to DOX (p < 0.05, n = 4; Fig. 4). Treatment
with NACA + DOX resulted in GSH and CYS levels that
were higher than those observed in the DOX-only group
(p's < 0.05, n = 4). Interestingly, in comparison with the
control group, the GSH level in the NACA-only group was
significantly increased (p < 0.05, n = 4), while the CYS lev-
els in the NACA-only group were similar to the control (p
> 0.4, n = 4).
NACA restored GSH/GSSG ratio
A change in cellular GSH content is usually accompanied
by a concomitant change in the GSSG (the oxidized form
of GSH) levels. The GSSG content in the DOX-only group
was increased by 61% compared to the control group.
NACA reduced the increased GSSG content to the control
group level (p > 0.05, n = 4; Fig. 4). The GSH/GSSG ratio
reflects accumulation of GSSG, thus is a more reliable
indicator of cellular redox status. While the ratio was
decreased by 47% upon administration of DOX, NACA
treatment restored it substantially (p < 0.01, n = 4) (Fig.
4). Interestingly, the GSH/GSSG ratio in the NACA-only
group was higher than in the control group, suggesting
that NACA provides cells with additional cysteine for GSH
synthesis (p < 0.05, n = 4).
NACA reduced lipid peroxidation induced by DOX
DOX at 5 μM elevated lipid peroxidation as indicated by
the increased detection of cellular TBA-MDA complex.
NACA significantly reduced lipid peroxidation compared
to the DOX-only group (p < 0.05, n = 4) (Table 1). Lipid
peroxidation in the NACA-only group did not differ from
the control group (p > 0.05, n = 4).
NACA restored activities of antioxidant enzymes: catalase 
(CAT), gluthathione peroxidase (GPx), gluthathione 
reductase (GR)
CAT activity was 61% lower in the DOX-only group than
in the control group (p < 0.05, n = 4), while NACA treat-
ment eliminated this reduction (p < 0.05, n = 4) (Table 2).
DOX reduced GPx activity by 50% compared to the con-
trol (p < 0.05, n = 4). NACA was capable of fully mitigat-
ing the reduction (p < 0.05, n = 4) (Table 2). GR activity
was 84% lower in DOX-only cells compared to the control
group (p < 0.01, n = 4), and NACA significantly restored
the reduction (p < 0.05, n = 4) (Table 2). Activity of CAT,
GPx, and GR did not differ between the control group and
NACA-only group.
Discussion
In the present study, DOX significantly reduced cell viabil-
ity in a concentration- and time-dependent fashion.
Though NACA reduced oxidative stress, it had only mini-
mal protective effects on DOX-induced cytotoxicity. Thus,
it appears that DOX-induced cell death may have involved
redox shift-independent mechanism(s). Previous studies
have shown that DOX toxicity can be mediated by the
redox-shift dependent pathway as well as by topoisomer-
ase II activation; the latter leads to DNA cleavage, caspase-
3 activation and eventually apoptosis [23,24]. The precise
contributions of ROS-dependent pathways and the topoi-
somerase- pathway to DOX-induced cell death remain to
be determined.
NACA was capable of restoring GSH, CYS, and GSH/GSSG
ratio that were reduced by DOX. NACA supplementation
reduced oxidative stress by at least two means. First, NACA
may supply cysteine required for GSH synthesis. Second,
NACA may convert GSSG to GSH by a non-enzymatic
thiol-disulfide exchange. This argument is supported by
the increased GSH level observed in the NACA-only
group. Our finding on the increased GSH levels in the
NACA-only group is in agreement with Offen et al. [22].
Offen et al. further suggested that NACA was also able to
reduce Cu2+-mediated free radical formation, through an
undetermined chemical mechanism [22].
NACA prevented the DOX-induced decrease of GR activ-
ity. A similar phenomenon of GR activity protection by
antioxidants was observed in a study on cadmium-
induced oxidative toxicity [25]. The mechanism of resto-
ration remains unclear, though one suggestion has been
made. GR-mediated reduction of GSSG to GSH is
NADPH-dependent. Regeneration of NADPH from
NADP+  requires glucose-6-phosphate dehydrogenaseBMC Pharmacology 2009, 9:7 http://www.biomedcentral.com/1471-2210/9/7
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Effect of NACA and NAC on DOX-induced toxicity in H9c2 cells Figure 2
Effect of NACA and NAC on DOX-induced toxicity in H9c2 cells. Cells were treated with NACA or NACA at 750 
μM for 2 h followed by exposure to freshly prepared cell culture medium with both DOX and NACA or NAC at designated 
concentrations for 24, 48, or 72 h. The concentrations of DOX were 0.25 μM, 0.75 μM, 2 μM, 5 μM, 20 μM, and 100 μM. Val-
ues are mean ± SD from three independent experiments performed in quadruplicate. Significance indicated by: αp < 0.05 com-
pared between DOX only and NACA + DOX; βp < 0.05 compared between DOX only and NAC + DOX.
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(G6PD). However, G6PD activity may also be reduced by
oxidative stress; thus, GR activity might be limited by the
G6PD-dependent supply of NADPH. It is possible that
NACA prevented DOX-induced decrease of G6PD activity.
In the present study, however, G6PD activity was not
measured, and additional studies are required to evaluate
this mechanism. It should be noted that although GR
plays an important role in regenerating endogenous GSH
from GSSG, new studies suggested that alternative mech-
anisms to reduce GSSG and other disulfides may just be
enough for animal's normal viability [26]. In addition to
the above pathways to increase cellular GSH content, glu-
tathione S-transferase (GST) may conjugate GSH directly
to oxidized derivatives of DOX and thus play a crucial role
in attenuating the elevated oxidative stress [27].
Increase or activation of endogenous ROS-scavenging
antioxidants or enzymes has been shown to protect cells
from oxidative damage. For instance, 3H-1,2-dithiole-3-
thione, a chemoprotective agent, protects against DOX-
mediated injury in cardiac cells by inducing cellular anti-
oxidants and enzymes such as GSH, CAT, GPx, GR, and
GST [28]. In the present study, the activities of CAT, GPx,
and GR in H9c2 cells were significantly decreased follow-
ing treatment with DOX, but their levels remained at near
control values in the presence of NACA, reflecting the res-
toration of a healthier cellular redox state.
CAT is particularly important in that its relatively low con-
stitutive level in cardiacmyocytes may predispose cardiac
muscle to oxidative stress damage [29]. It has been shown
that CAT activity can be significantly reduced by DOX
[30,31]. In the present study, NACA was able to prevent
the loss of CAT activity caused by subsequent to DOX.
Cardiac muscle is very susceptible to oxidative damage
due in part to the rapid inactivation of GPx [29]. Overex-
pression of GPx in endothelial cells and myocytes signifi-
cantly decreases DOX-induced NF-kB activation which
leads to apoptosis [32]. In the present study, we found
that the enzymatic activity of GPx, which utilizes GSH as
a substrate to reduce H2O2 to H2O, is decreased by DOX.
This fall in GPx activity might be a result of the decrease in
GSH, as suggested by others [33]. The increased intracel-
lular GSH content in the NACA group might activate the
GSH-dependent GPx, thereby preventing the accumula-
tion of H2O2. Thus, the ability of NACA to reactivate GPx
activity in our study is further evidence of cardioprotec-
tion.
Conclusion
Though NACA was able to provide oxidative relief, it only
had minimal protective effect on DOX-induced cytotoxic-
ity. NACA prevented oxidative stress by elevation of GSH
and CYS, reduction of ROS and lipid peroxidation, and
restoration of antioxidant enzyme activities. Further stud-
ies to identify various mechanisms of cytotoxicity and
their inter-relationships, if any, which lead to DOX-
induced cell death are warranted.
Methods
Chemicals and reagents
N-(1-pyrenyl)-maleimide (NPM) was purchased from
Aldrich (Milwaukee, WI, USA). N-acetylcysteine amide
(NACA) was obtained from David Pharmaceuticals (New
York, NY, USA). HPLC grade solvents were purchased from
Fisher Scientific (Fair Lawn, NJ, USA). All other chemicals
were purchased from Sigma (St. Louis, MO, USA).
Cell culture and toxicity studies
H9c2 cells, a clonal line of cardiomyocytes derived from
embryonic rat heart tissue, were purchased from the Amer-
ican Type Culture Collection (ATCC, Manassas, VA, USA).
H9c2 cells exhibit many of the properties of cardiac muscle,
including electrophysiological activity, ion channels, and
autonomic receptors [34]. This cell line has been previously
used in doxorubicin-related cytotoxicity studies [35,36].
Following the protocol provided by ATCC, the cells were
cultured in a complete medium consisting of Dulbecco's
DCF-fluorescence intensity in H9c2 cells after treatment  with DOX in presence or absence of NACA Figure 3
DCF-fluorescence intensity in H9c2 cells after treat-
ment with DOX in presence or absence of NACA. 
Cells were seeded in 24-well plates at a density of 1 × 
105cell/well. Cells were treated with or without NACA for 2 
h. Then the cell medium was discarded and freshly prepared 
cell medium containing 5 μM DOX in presence or absence of 
750 μM NACA was used to treat the cells for a period of 24 
h. The results are presented as percent of the DCF-fluores-
cence observed in the control group. Values are mean ± SD 
from three independent experiments performed in quadru-
plicate. Significance indicated by: *p < 0.05 compared to con-
trol group; ** p < 0.05 compared to the DOX-only group.
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modified Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 4 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/
L glucose, and 1% (v/v) penicillin and streptomycin. The
cultures were maintained at 37° in a 5% CO2 humidified
atmosphere. Cells were subcultured at a 1:4 ratio every 3
days using 75 cm2 tissue culture flasks.
After termination of experiments, a serine borate buffer
(SBB) was used during cell homogenate preparation to
prevent potential oxidation of biothiols in GSH, CYS, and
GSSG analyses, and of in the lipid peroxidation assay. The
SBB buffer contains 100 mM Tris-HCl, 10 mM borate, 5
mM serine, and 1 mM diethylenetriaminepentacetic acid
with the final pH adjusted to 7.0 using concentrated
NaOH. The cell samples are homogenized in the SBB
buffer with a tissue homogenizer (Model 985-370, type 2,
Biospec Products, Inc.) on ice for 2 min, with 5 s intervals
of homogenization.
GSH, CYS, GSSG levels, and GSH/GSSG ratio in H9c2 cells after treatment with DOX in presence or absence of NACA Figure 4
GSH, CYS, GSSG levels, and GSH/GSSG ratio in H9c2 cells after treatment with DOX in presence or absence 
of NACA. H9c2 cells were plated in 75 cm2 tissue culture flasks at a density of 4 × 104 cells/cm2. Cells were treated with or 
without NACA for 2 h. Then the cell medium was discarded and freshly prepared cell medium containing 5 μM DOX in pres-
ence or absence of 750 μM NACA was used to treat the cells for a period of 24 h. Values are mean ± SD from three independ-
ent experiments performed in quadruplicate. Significance indicated by: *p < 0.05 compared to control group; ** p < 0.05 
compared to the DOX-only group.
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Table 1: Lipid peroxidation after DOX and NACA treatment in 
H9c2 cells.
Group TBA-MDA (nmol/100 mg protein)
Control 0.92 ± 0.02
DOX (5 μM) 1.55 ± 0.17 *
NACA (750 μM) 0.87 ± 0.04
DOX (5 μM)+ NACA (750 μM) 0.89 ± 0.02**
Significance indicated by: *p < 0.05 compared to control cells; ** p < 
0.05 compared to DOX-only group.BMC Pharmacology 2009, 9:7 http://www.biomedcentral.com/1471-2210/9/7
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Cytotoxicity of DOX in H9c2 cells
To choose a sublethal concentration of NACA and NAC
for the study on their ability to protect cells from DOX-
induced toxicity, we first exposed H9c2 cells with NACA
or NAC at 0.25 mM, 0.50 mM, 0.75 mM, 1 mM, 2 mM, 5
mM, 10 mM, and 20 mM for 24 h. Untreated cells were
used as the control for each experiment. At 1.0 mM of
NACA or NAC, the cell viability did not differ from the
control group. We conservatively selected a nontoxic con-
centration, 0.75 mM, for both antioxidants for the subse-
quent experiments.
To determine effectiveness of NACA and NAC in protec-
tion of H9c2 cells from DOX-induced toxicity, cells were
treated with NACA or NAC at 0.75 mM for 2 h followed
by exposure to freshly prepared cell culture medium with
DOX in presence or absence of NACA or NAC at desig-
nated concentrations. The concentrations of DOX were
0.25 μM, 0.75 μM, 2 μM, 5 μM, 20 μM, and 100 μM. The
exposure durations were 24 h, 48 h, or 48 h. Cells incu-
bated with NACA or NAC alone were used as the control.
MTS assay
The MTS bioreduction assay (Cell Titer 96® Aqueous One
Solution Assay, Promega) is an assay based on the biore-
duction of 3-(4,5-dimethyl thiazol-2-yl)-5-(3-car-
boxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) by viable cells to a colored formazan product that
is soluble in culture media [37]. Absorbance at 490 nm is
proportional to the number of living cells in the culture.
Intracellular ROS measurement
Intracellular ROS generation was measured using a well
characterized probe, 2', 7'-dichlorofluorescin diacetate
(DCFH-DA) [38]. DCFH-DA is hydrolyzed by esterases to
dichlorofluorescin (DCFH), which is trapped within the
cell. This nonfluorescent molecule is then oxidized to fluo-
rescent dichlorofluorescin (DCF) by action of cellular oxi-
dants. After exposure to 5 μM DOX, with or without
treatment with 750 μM NACA, the cells (106/ml) were
incubated in 2 ml of 140 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 5.6 mM glucose, 1.5 mM CaCl2, and 20 mM Hepes-
Na, pH 7.4, and allowed to take up 5 μM DCFH2-DA at
37°C for 20 min in an atmosphere of 95% air and 5% CO2.
After loading samples on 96 well plates, DCF fluorescence
was measured at 485 nm excitation and 520 nm emission.
GSH and CYS measurement
Cellular levels of GSH and cysteine were determined by
HPLC [39]. Cells were seeded at a density of 4 × 104 cells/
cm2 on 75 cm2 flasks, and the flasks were incubated for 24
h with fresh medium containing DOX (5 μM), or DOX (5
μM) + NACA (750 μM), or NACA (750 μM) at 37°C. Fol-
lowing the incubation period, the cells were removed and
homogenized. Twenty μl of diluted cell homogenate were
added to 230 μl of serine borate buffer and 750 μl of NPM
(1 mM in acetonitrile). NPM reacts with free sulfhydryl
groups to form fluorescent derivatives which yield fluores-
cent adducts that can be detected fluorimetrically (λex =
330 nm, λem = 376 nm). After incubation at room tem-
perature for 5 min, the samples were acidified with 10 μl
of 2 N HCl to stop the reaction. The derivatized samples
were filtered through a 0.45 μm acrodisc and then injected
onto the HPLC column.
Glutathione disulfide (GSSG) measurement
H9c2 cells were seeded in 75 cm2 tissue culture flasks at a
density of 4 × 104 cells/cm2. The cells were treated for 24 h
with 5 μM DOX, 750 μM NACA, or 5 μM DOX + 750 μM
NACA. Untreated cells served as controls. Sixteen μl of
6.25% 2-vinylpyridine in absolute ethanol were added to
84 μl of cell homogenate. This suspension was incubated at
room temperature for 60 minutes to block the thiol group
of the GSH already present. NADPH (95 μl of 2 mg/ml) in
nanopure water and 5 μl of 2 units/ml glutathione reduct-
ase were added to reduce GSSG. An aliquot of 100 μl of the
treated samples was diluted with 150 μl H2O, and then
immediately derivatized with 750 μl of 1.0 mM NPM. Flu-
orescence was then measured (λex = 330 nm and λem =
376 nm) (Thermo Electron Corp., Austin, TX, USA).
Lipid peroxidation measurement
Malondialdehyde (MDA) is a thiobarbituric acid reactive
substance (TBAR). The extent of cellular lipid peroxida-
tion was determined by measuring concentrations of TBA-
MDA complex. Cell homogenate (350 μl), 100 μl of 500
ppm butylated hydroxytoluene, and 550 μl of 10%
trichloroacetic acid were combined, and the suspension
was boiled for 30 min. An aliquot (500 μl) of the super-
natant was removed and 500 μl of thiobarbituric acid
added. From this solution, 500 μl was removed and added
to 1.0 ml of n-butanol. This mixture was vortexed, and
centrifuged for 5 min at 110 × g to facilitate phase separa-
Table 2: Antioxidant enzyme activities.
Group Catalase (mU/mg protein) GPx (ΔA/min/mg protein) GR (mU/mg protein)
Control 10.94 ± 2.13 24.77 ± 3.91 5.13 ± 0.09
DOX (5 μM) 4.30 ± 0.45* 12.50 ± 1.74* 0.83 ± 0.04*
NACA (750 μM) 12.85 ± 0.25 21.44 ± 2.39 4.58 ± 0.60
DOX (5 μM)+ NACA (750 μM) 13.13 ± 2.17** 19.31 ± 3.07** 4.22 ± 0.53**
Significance indicated by: *p < 0.05 compared to control cells; **p < 0.05 compared to DOX-only group.BMC Pharmacology 2009, 9:7 http://www.biomedcentral.com/1471-2210/9/7
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tion. Fluorescence was then measured (λex = 515 nm and
λem = 550 nm) [40].
Measurement of antioxidant enzymes
H9c2 cells were plated in 75 cm2 tissue culture flasks at a
density of 4 × 104 cells/cm2 and allowed to attach for 24 h
in complete cell culture medium. The cells were then
divided into four groups for 24 h treatment, as follows: 1)
control, 2) 5 μM DOX, 3) 5 μM DOX + 750 μM NACA,
and 4) 750 μM NACA. Assays for antioxidant enzymes
were then carried out.
Catalase (CAT) activity assays
Catalase activity was determined spectrophotometrically
as described by Aebi [41]. Cell homogenates were diluted
with 50 mM phosphate buffer (pH = 7.0). The exponen-
tial decrease of 10 mM hydrogen peroxide was measured
at 240 nm in the presence of cell homogenate. Reaction
mixtures without cell homogenate were used as tissue
blanks.
Glutathione peroxidase (GPx) activity determination
Glutathione peroxidase activity was determined by the
method of Paglia and Valentine [42]. Cell homogenates
were diluted with phosphate buffer (pH 7.6). Tert-butyl
hydroperoxide was first reduced by glutathione peroxidase
and then recycled by glutathione reductase coupled with
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidation. The rate of decrease in NADPH was monitored
spectrophotometrically at 340 nm as a measure of GPx activ-
ity.
Glutathione reductase (GR) activity determination
GR activity was determined using the method of Carlberg
and Mannervik [43]. Glutathione reductase is required for
the NADPH-dependent conversion of oxidized glutath-
ione (GSSG) to reduced glutathione (GSH). Cell homoge-
nates were diluted with phosphate buffer (pH = 7.5). The
exponential decrease of NADPH was measured spectro-
photometrically at 340 nm in the presence of cell
homogenate. Reaction mixtures in which potassium
phosphate buffer was used instead of glutathione
disulfide in phosphate buffer were used as blanks.
Protein determination
Protein levels were determined by the Bradford method
with Coomassie blue (Bio-Rad) [44]. Two and a half mil-
limeters of the diluted reagent were added to 0.05 ml of a
bovine serum albumin standard solution containing 10 to
100 mg/ml protein. This mixture was incubated at room
temperature for 5 to 10 minutes and the optical density
was measured at 595 nm.
Statistical analysis
The data are presented as the mean ± SD. One-way analy-
sis of variance (ANOVA) and Student-Newman-Keuls
multiple comparison tests were used to analyze the signif-
icance of the differences between treatment groups. Statis-
tical significance is set at 0.05.
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